 Connection
Erin Harvey to Australia
This is a "connection" page, showing publications Erin Harvey has written about Australia.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.540 |
|
|
|
-
Harvey ES, Langton D, Katelaris C, Stevens S, Farah CS, Gillman A, Harrington J, Hew M, Kritikos V, Radhakrishna N, Bardin P, Peters M, Reynolds PN, Upham JW, Baraket M, Bowler S, Bowden J, Chien J, Chung LP, Grainge C, Jenkins C, Katsoulotos GP, Lee J, McDonald VM, Reddel HK, Rimmer J, Wark PAB, Gibson PG. Mepolizumab effectiveness and identification of super-responders in severe asthma. Eur Respir J. 2020 05; 55(5).
Score: 0.159
-
Hamada Y, Thomas D, Harvey ES, Stevens S, Fricker M, Lewthwaite H, McDonald VM, Gillman A, Hew M, Kritikos V, Upham JW, Gibson PG. Distinct trajectories of treatment response to mepolizumab toward remission in patients with severe eosinophilic asthma. Eur Respir J. 2025 Jan; 65(1).
Score: 0.055
-
Hamada Y, Gibson PG, Harvey ES, Stevens S, Lewthwaite H, Fricker M, McDonald VM, Gillman A, Hew M, Kritikos V, Upham JW, Thomas D. Early Treatment Response to Mepolizumab Predicts Clinical Remission in Severe Eosinophilic Asthma. J Allergy Clin Immunol Pract. 2025 Feb; 13(2):333-342.e9.
Score: 0.054
-
Thomas D, McDonald VM, Stevens S, Harvey ES, Baraket M, Bardin P, Bowden JJ, Bowler S, Chien J, Chung LP, Gillman A, Hew M, Hodge S, James A, Jenkins C, Katelaris CH, Katsoulotos GP, Langton D, Lee J, Marks G, Peters M, Radhakrishna N, Reynolds PN, Rimmer J, Sivakumaran P, Upham JW, Wark P, Yang IA, Gibson PG. Biologics (mepolizumab and omalizumab) induced remission in severe asthma patients. Allergy. 2024 02; 79(2):384-392.
Score: 0.050
-
Vertigan AE, Harvey ES, Beyene T, Van Buskirk J, Holliday EG, Bone SL, McDonald VM, Horvat JC, Murphy VE, Jensen ME, Morgan GG, Zosky GR, Peters M, Farah CS, Jenkins CR, Katelaris CH, Harrington J, Langton D, Bardin P, Katsoulotos GP, Upham JW, Chien J, Bowden JJ, Rimmer J, Bell R, Gibson PG. Impact of Landscape Fire Smoke Exposure on Patients With Asthma With or Without Laryngeal Hypersensitivity. J Allergy Clin Immunol Pract. 2023 10; 11(10):3107-3115.e2.
Score: 0.049
-
Kritikos V, Harvey ES, Stevens S, Katelaris CH, Langton D, Rimmer J, Farah CS, Gillman A, Hew M, Radhakrishna N, Thomas D, Gibson PG. Comorbidities Modify the Phenotype but Not the Treatment Effectiveness to Mepolizumab in Severe Eosinophilic Asthma. J Allergy Clin Immunol Pract. 2023 03; 11(3):885-895.e13.
Score: 0.048
-
Beyene T, Harvey ES, Van Buskirk J, McDonald VM, Jensen ME, Horvat JC, Morgan GG, Zosky GR, Jegasothy E, Hanigan I, Murphy VE, Holliday EG, Vertigan AE, Peters M, Farah CS, Jenkins CR, Katelaris CH, Harrington J, Langton D, Bardin P, Katsoulotos GP, Upham JW, Chien J, Bowden JJ, Rimmer J, Bell R, Gibson PG. 'Breathing Fire': Impact of Prolonged Bushfire Smoke Exposure in People with Severe Asthma. Int J Environ Res Public Health. 2022 06 16; 19(12).
Score: 0.046
-
Thomas D, Harvey ES, McDonald VM, Stevens S, Upham JW, Katelaris CH, Kritikos V, Gillman A, Harrington J, Hew M, Bardin P, Peters M, Reynolds PN, Langton D, Baraket M, Bowden JJ, Bowler S, Chien J, Chung LP, Farah CS, Grainge C, Jenkins C, Katsoulotos GP, Lee J, Radhakrishna N, Reddel HK, Rimmer J, Sivakumaran P, Wark PAB, Gibson PG. Mepolizumab and Oral Corticosteroid Stewardship: Data from the Australian Mepolizumab Registry. J Allergy Clin Immunol Pract. 2021 07; 9(7):2715-2724.e5.
Score: 0.042
-
Denton E, Hore-Lacy F, Radhakrishna N, Gilbert A, Tay T, Lee J, Dabscheck E, Harvey ES, Bulathsinhala L, Fingleton J, Price D, Gibson PG, O'Hehir R, Hew M. Severe Asthma Global Evaluation (SAGE): An Electronic Platform for Severe Asthma. J Allergy Clin Immunol Pract. 2019 May - Jun; 7(5):1440-1449.
Score: 0.037
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|